393 related articles for article (PubMed ID: 22084392)
1. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.
Tugal-Tutkun I; Kadayifcilar S; Khairallah M; Lee SC; Ozdal P; Özyazgan Y; Song JH; Yu HG; Lehner V; de Cordoue A; Bernard O; Gül A
Ocul Immunol Inflamm; 2017 Feb; 25(1):62-70. PubMed ID: 26829647
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
4. Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.
Tugal-Tutkun I; Pavesio C; De Cordoue A; Bernard-Poenaru O; Gül A
Ocul Immunol Inflamm; 2018; 26(7):1023-1033. PubMed ID: 29370572
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).
Davatchi F; Shams H; Rezaipoor M; Sadeghi-Abdollahi B; Shahram F; Nadji A; Chams-Davatchi C; Akhlaghi M; Faezi T; Naderi N
Int J Rheum Dis; 2010 Aug; 13(3):246-52. PubMed ID: 20704622
[TBL] [Abstract][Full Text] [Related]
6. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
7. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine in severe uveitis of Behçet's disease.
Saadoun D; Wechsler B; Terrada C; Hajage D; Le Thi Huong D; Resche-Rigon M; Cassoux N; Le Hoang P; Amoura Z; Bodaghi B; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1733-8. PubMed ID: 20665749
[TBL] [Abstract][Full Text] [Related]
12. Does lowering hyperhomocysteinemia by folic acid beneficial for oculo-Behcet's disease? A pilot study.
Houman MH; Naffati H; Khanfir M; Ghannouchi M; Ben Ghorbel I; Lamloum M; El Matri L; Hamzaoui K; Jeddi A; Miled M; Fki M
Tunis Med; 2007 Jun; 85(6):450-3. PubMed ID: 17644895
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
14. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
17. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
20. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
